guest ::
| Home > Publications database > Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. > print |
| Home > Publications database > Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. > print |
| 001 | 129194 | ||
| 005 | 20240228145549.0 | ||
| 024 | 7 | _ | |a 10.1038/bmt.2017.119 |2 doi |
| 024 | 7 | _ | |a pmid:28650448 |2 pmid |
| 024 | 7 | _ | |a 0268-3369 |2 ISSN |
| 024 | 7 | _ | |a 0951-3078 |2 ISSN |
| 024 | 7 | _ | |a 1476-5365 |2 ISSN |
| 024 | 7 | _ | |a altmetric:21362612 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-05199 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Zeisbrich, M. |b 0 |
| 245 | _ | _ | |a Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. |
| 260 | _ | _ | |a London |c 2017 |b Nature Publishing Group55086 |
| 264 | _ | 1 | |3 online |2 Crossref |b Springer Science and Business Media LLC |c 2017-06-26 |
| 264 | _ | 1 | |3 print |2 Crossref |b Springer Science and Business Media LLC |c 2017-10-01 |
| 264 | _ | 1 | |3 print |2 Crossref |b Springer Science and Business Media LLC |c 2017-10-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1511266448_9859 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a There is increasing evidence that endothelial dysfunction is involved in refractoriness of acute GvHD (aGvHD). Here we investigated the hypothesis that another endothelial complication, transplant-associated thrombotic microangiopathy (TMA), contributes to the pathogenesis of aGvHD refractoriness. TMA was retrospectively assessed in 771 patients after allogeneic stem cell transplantation (alloSCT). Incidences of TMA and refractory aGvHD were correlated with biomarkers of endothelial damage obtained before alloSCT for patients receiving or not receiving statin-based endothelial prophylaxis (SEP). Diagnostic criteria for TMA and refractory aGvHD were met by 41 (5.3%) and 76 (10%) patients, respectively. TMA was overrepresented in patients with refractory aGvHD (45.0 vs 2.3% in all other patients, P<0.001). TMA independently increased mortality. Elevated pretransplant suppressor of tumorigenicity-2 and nitrates along with high-risk variants of the thrombomodulin gene were associated with increased risk of TMA. In contrast, SEP abolished the unfavorable outcome predicted by pretransplant biomarkers on TMA risk. Patients on SEP had a significantly lower risk of TMA (P=0.001) and refractory aGvHD (P=0.055) in a multivariate multistate model. Our data provide evidence that TMA contributes to the pathogenesis of aGvHD refractoriness. Patients with an increased TMA risk can be identified pretransplant and may benefit from pharmacological endothelium protection. |
| 536 | _ | _ | |a 313 - Cancer risk factors and prevention (POF3-313) |0 G:(DE-HGF)POF3-313 |c POF3-313 |f POF III |x 0 |
| 542 | _ | _ | |i 2017-06-26 |2 Crossref |u https://www.springer.com/tdm |
| 542 | _ | _ | |i 2017-06-26 |2 Crossref |u https://www.springer.com/tdm |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Becker, Natalia |0 P:(DE-He78)ecb33fb615e08035fdcefcaebfdff8f0 |b 1 |u dkfz |
| 700 | 1 | _ | |a Benner, A. |0 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |b 2 |u dkfz |
| 700 | 1 | _ | |a Radujkovic, A. |b 3 |
| 700 | 1 | _ | |a Schmitt, K. |b 4 |
| 700 | 1 | _ | |a Beimler, J. |b 5 |
| 700 | 1 | _ | |a Ho, A. D. |b 6 |
| 700 | 1 | _ | |a Zeier, M. |b 7 |
| 700 | 1 | _ | |a Dreger, P. |b 8 |
| 700 | 1 | _ | |a Luft, T. |b 9 |
| 773 | 1 | 8 | |a 10.1038/bmt.2017.119 |b Springer Science and Business Media LLC |d 2017-06-26 |n 10 |p 1399-1405 |3 journal-article |2 Crossref |t Bone Marrow Transplantation |v 52 |y 2017 |x 0268-3369 |
| 773 | _ | _ | |a 10.1038/bmt.2017.119 |g Vol. 52, no. 10, p. 1399 - 1405 |0 PERI:(DE-600)2004030-1 |n 10 |p 1399-1405 |t Bone marrow transplantation |v 52 |y 2017 |x 0268-3369 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:129194 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)ecb33fb615e08035fdcefcaebfdff8f0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |2 G:(DE-HGF)POF3-300 |v Cancer risk factors and prevention |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BONE MARROW TRANSPL : 2014 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l Biostatistik |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| 999 | C | 5 | |a 10.1016/S0140-6736(09)60237-3 |9 -- missing cx lookup -- |1 JL Ferrara |p 1550 - |2 Crossref |u Ferrara JL, Levine JE, Reddy P, Holler E . Graft-versus-host disease. Lancet 2009; 373: 1550–1561. |t Lancet |v 373 |y 2009 |
| 999 | C | 5 | |a 10.1155/2011/601953 |9 -- missing cx lookup -- |1 JR Westin |p 601953 - |2 Crossref |u Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH et al. Steroid-refractory acute GVHD: predictors and outcomes. Adv Hematol 2011; 2011: 601953. |t Adv Hematol |v 2011 |y 2011 |
| 999 | C | 5 | |a 10.1182/blood-2011-02-334821 |9 -- missing cx lookup -- |1 T Luft |p 1685 - |2 Crossref |u Luft T, Dietrich S, Falk C, Conzelmann M, Hess M, Benner A et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 2011; 118: 1685–1692. |t Blood |v 118 |y 2011 |
| 999 | C | 5 | |a 10.1016/j.bbmt.2012.09.018 |9 -- missing cx lookup -- |1 S Dietrich |p 22 - |2 Crossref |u Dietrich S, Falk CS, Benner A, Karamustafa S, Hahn E, Andrulis M et al. Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment. Biol Blood Marrow Transplant 2013; 19: 22–27. |t Biol Blood Marrow Transplant |v 19 |y 2013 |
| 999 | C | 5 | |a 10.3324/haematol.2013.090209 |9 -- missing cx lookup -- |1 S Dietrich |p 541 - |2 Crossref |u Dietrich S, Okun JG, Schmidt K, Falk CS, Wagner AH, Karamustafa S et al. High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus-host disease in the absence of statin therapy. Haematologica 2014; 99: 541–547. |t Haematologica |v 99 |y 2014 |
| 999 | C | 5 | |a 10.1200/JCO.2013.54.4056 |9 -- missing cx lookup -- |1 SP Rachakonda |p 3421 - |2 Crossref |u Rachakonda SP, Penack O, Dietrich S, Blau O, Blau IW, Radujkovic A et al. Single-nucleotide polymorphisms within the thrombomodulin gene (THBD) predict mortality in patients with graft-versus-host disease. J Clin Oncol 2014; 32: 3421–3427. |t J Clin Oncol |v 32 |y 2014 |
| 999 | C | 5 | |a 10.1111/j.1537-2995.2004.00700.x |9 -- missing cx lookup -- |1 JN George |p 294 - |2 Crossref |u George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB . Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 2004; 44: 294–304. |t Transfusion |v 44 |y 2004 |
| 999 | C | 5 | |a 10.2215/CJN.02070508 |9 -- missing cx lookup -- |1 S Changsirikulchai |p 345 - |2 Crossref |u Changsirikulchai S, Myerson D, Guthrie KA, McDonald GB, Alpers CE, Hingorani SR . Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. Clin J Am Soc Nephrol 2009; 4: 345–353. |t Clin J Am Soc Nephrol |v 4 |y 2009 |
| 999 | C | 5 | |a 10.1016/j.blre.2014.11.001 |9 -- missing cx lookup -- |1 S Jodele |p 191 - |2 Crossref |u Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 2015; 29: 191–204. |t Blood Rev |v 29 |y 2015 |
| 999 | C | 5 | |a 10.1182/blood-2011-02-321315 |9 -- missing cx lookup -- |1 BL Laskin |p 1452 - |2 Crossref |u Laskin BL, Goebel J, Davies SM, Jodele S . Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 2011; 118: 1452–1462. |t Blood |v 118 |y 2011 |
| 999 | C | 5 | |a 10.1056/NEJMoa1213299 |9 -- missing cx lookup -- |1 MT Vander Lugt |p 529 - |2 Crossref |u Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med 2013; 369: 529–539. |t N Engl J Med |v 369 |y 2013 |
| 999 | C | 5 | |a 10.1016/j.yjmcc.2013.03.020 |9 -- missing cx lookup -- |1 S Demyanets |p 16 - |2 Crossref |u Demyanets S, Kaun C, Pentz R, Krychtiuk KA, Rauscher S, Pfaffenberger S et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol 2013; 60: 16–26. |t J Mol Cell Cardiol |v 60 |y 2013 |
| 999 | C | 5 | |a 10.1016/j.amjcard.2015.01.034 |9 -- missing cx lookup -- |1 DA Pascual-Figal |p 3B - |2 Crossref |u Pascual-Figal DA, Januzzi JL . The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol 2015; 115 (7 Suppl): 3B–7B. |t Am J Cardiol |v 115 |y 2015 |
| 999 | C | 5 | |a 10.1016/j.cardfail.2012.01.008 |9 -- missing cx lookup -- |1 SJ Aldous |p 304 - |2 Crossref |u Aldous SJ, Richards AM, Troughton R, Than M . ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J Card Fail 2012; 18: 304–310. |t J Card Fail |v 18 |y 2012 |
| 999 | C | 5 | |a 10.1182/blood-2014-10-606830 |9 -- missing cx lookup -- |1 DK Reichenbach |p 3183 - |2 Crossref |u Reichenbach DK, Schwarze V, Matta BM, Tkachev V, Lieberknecht E, Liu Q et al. The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood 2015; 125: 3183–3192. |t Blood |v 125 |y 2015 |
| 999 | C | 5 | |a 10.1097/00007890-197410000-00001 |9 -- missing cx lookup -- |1 H Glucksberg |p 295 - |2 Crossref |u Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304. |t Transplantation |v 18 |y 1974 |
| 999 | C | 5 | |a 10.1053/j.seminhematol.2011.10.001 |9 -- missing cx lookup -- |1 A Rovo |p 25 - |2 Crossref |u Rovo A, Tichelli A, Late Effects Working Party of the European Group for B, Marrow T . Cardiovascular complications in long-term survivors after allogeneic hematopoietic stem cell transplantation. Semin Hematol 2012; 49: 25–34. |t Semin Hematol |v 49 |y 2012 |
| 999 | C | 5 | |1 DK Cheuk |y 2015 |2 Crossref |u Cheuk DK, Chiang AK, Ha SY, Chan GC . Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation. Cochrane Database Syst Rev 2015; 5: CD009311. |
| 999 | C | 5 | |a 10.1016/j.bbmt.2005.06.001 |9 -- missing cx lookup -- |1 VT Ho |p 571 - |2 Crossref |u Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571–575. |t Biol Blood Marrow Transplant |v 11 |y 2005 |
| 999 | C | 5 | |a 10.3324/haematol.10699 |9 -- missing cx lookup -- |1 T Ruutu |p 95 - |2 Crossref |u Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007; 92: 95–100. |t Haematologica |v 92 |y 2007 |
| 999 | C | 5 | |1 National Kidney F |y 2002 |2 Crossref |u National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1–266. |
| 999 | C | 5 | |a 10.1002/sim.4780030106 |9 -- missing cx lookup -- |1 R Simon |p 35 - |2 Crossref |u Simon R, Makuch RW . A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med 1984; 3: 35–44. |t Stat Med |v 3 |y 1984 |
| 999 | C | 5 | |a 10.2307/2533277 |9 -- missing cx lookup -- |1 PM Grambsch |p 1469 - |2 Crossref |u Grambsch PM, Therneau TM, Fleming TR . Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics 1995; 51: 1469–1482. |t Biometrics |v 51 |y 1995 |
| 999 | C | 5 | |a 10.1002/sim.2712 |9 -- missing cx lookup -- |1 H Putter |p 2389 - |2 Crossref |u Putter H, Fiocco M, Geskus RB . Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007; 26: 2389–2430. |t Stat Med |v 26 |y 2007 |
| 999 | C | 5 | |a 10.1002/sim.1611 |9 -- missing cx lookup -- |1 N Holländer |p 1701 - |2 Crossref |u Holländer N, Sauerbrei W, Schumacher M . Confidence intervals for the effect of a prognostic factor after selection of an 'optimal' cutpoint. Stat Med 2004; 23: 1701–1713. |t Stat Med |v 23 |y 2004 |
| 999 | C | 5 | |a 10.1111/j.1365-2141.2006.06126.x |9 -- missing cx lookup -- |1 F Peyvandi |p 187 - |2 Crossref |u Peyvandi F, Siboni SM, Lambertenghi Deliliers D, Lavoretano S, De Fazio N, Moroni B et al. Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation. Br J Haematol 2006; 134: 187–195. |t Br J Haematol |v 134 |y 2006 |
| 999 | C | 5 | |a 10.1177/1076029615598221 |9 -- missing cx lookup -- |1 O Elsallabi |p 12 - |2 Crossref |u Elsallabi O, Bhatt VR, Dhakal P, Foster KW, Tendulkar KK . Hematopoietic stem cell transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost 2016; 22: 12–20. |t Clin Appl Thromb Hemost |v 22 |y 2016 |
| 999 | C | 5 | |a 10.1038/bmt.2008.419 |9 -- missing cx lookup -- |1 Y Inamoto |p 43 - |2 Crossref |u Inamoto Y, Ito M, Suzuki R, Nishida T, Iida H, Kohno A et al. Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. Bone Marrow Transplant 2009; 44: 43–49. |t Bone Marrow Transplant |v 44 |y 2009 |
| 999 | C | 5 | |a 10.1038/sj.bmt.1704512 |9 -- missing cx lookup -- |1 T Nishida |p 1143 - |2 Crossref |u Nishida T, Hamaguchi M, Hirabayashi N, Haneda M, Terakura S, Atsuta Y et al. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplant 2004; 33: 1143–1150. |t Bone Marrow Transplant |v 33 |y 2004 |
| 999 | C | 5 | |1 J Chapin |y 2014 |2 Crossref |u Chapin J, Shore T, Forsberg P, Desman G, Van Besien K, Laurence J . Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clin Adv Hematol Oncol 2014; 12: 565–573. |
| 999 | C | 5 | |a 10.1038/sj.bmt.1705758 |9 -- missing cx lookup -- |1 ED Batts |p 709 - |2 Crossref |u Batts ED, Lazarus HM . Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant 2007; 40: 709–719. |t Bone Marrow Transplant |v 40 |y 2007 |
| 999 | C | 5 | |a 10.1182/blood-2014-03-564997 |9 -- missing cx lookup -- |1 S Jodele |p 645 - |2 Crossref |u Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 2014; 124: 645–653. |t Blood |v 124 |y 2014 |
| 999 | C | 5 | |a 10.1182/blood-2014-11-611780 |9 -- missing cx lookup -- |1 S Ito |p 10 - |2 Crossref |u Ito S, Barrett AJ . ST2: the biomarker at the heart of GVHD severity. Blood 2015; 125: 10–11. |t Blood |v 125 |y 2015 |
| 999 | C | 5 | |a 10.1084/jem.20071868 |9 -- missing cx lookup -- |1 AM Miller |p 339 - |2 Crossref |u Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205: 339–346. |t J Exp Med |v 205 |y 2008 |
| 999 | C | 5 | |a 10.1111/eci.12282 |9 -- missing cx lookup -- |1 J Sánchez-Más |p 643 - |2 Crossref |u Sánchez-Más J, Lax A, Asensio-López Mdel C, Fernandez-Del Palacio MJ, Caballero L, Santarelli G et al. Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers. Eur J Clin Invest 2014; 44: 643–651. |t Eur J Clin Invest |v 44 |y 2014 |
| 999 | C | 5 | |a 10.1373/clinchem.2012.192153 |9 -- missing cx lookup -- |1 EE Coglianese |p 1673 - |2 Crossref |u Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, McCabe EL et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem 2012; 58: 1673–1681. |t Clin Chem |v 58 |y 2012 |
| 999 | C | 5 | |a 10.1161/CIRCULATIONAHA.112.129437 |9 -- missing cx lookup -- |1 TJ Wang |p 1596 - |2 Crossref |u Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012; 126: 1596–1604. |t Circulation |v 126 |y 2012 |
| 999 | C | 5 | |a 10.1016/j.jacc.2008.09.027 |9 -- missing cx lookup -- |1 J Bartunek |p 2166 - |2 Crossref |u Bartunek J, Delrue L, Van Durme F, Muller O, Casselman F, De Wiest B et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 2008; 52: 2166–2174. |t J Am Coll Cardiol |v 52 |y 2008 |
| 999 | C | 5 | |a 10.1182/blood-2014-06-584789 |9 -- missing cx lookup -- |1 DM Ponce |p 199 - |2 Crossref |u Ponce DM, Hilden P, Mumaw C, Devlin SM, Lubin M, Giralt S et al. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood 2015; 125: 199–205. |t Blood |v 125 |y 2015 |
| 999 | C | 5 | |a 10.1038/82219 |9 -- missing cx lookup -- |1 B Kwak |p 1399 - |2 Crossref |u Kwak B, Mulhaupt F, Myit S, Mach F . Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399–1402. |t Nat Med |v 6 |y 2000 |
| 999 | C | 5 | |a 10.1161/01.CIR.100.3.230 |9 -- missing cx lookup -- |1 PM Ridker |p 230 - |2 Crossref |u Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E . Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230–235. |t Circulation |v 100 |y 1999 |
| 999 | C | 5 | |1 H Amuro |y 2010 |2 Crossref |u Amuro H, Ito T, Miyamoto R, Sugimoto H, Torii Y, Son Y et al. Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production. Arthritis Rheum 2010; 62: 2073–2085. |
| 999 | C | 5 | |a 10.1016/j.atherosclerosis.2010.03.034 |9 -- missing cx lookup -- |1 K Sato |p 33 - |2 Crossref |u Sato K, Nuki T, Gomita K, Weyand CM, Hagiwara N . Statins reduce endothelial cell apoptosis via inhibition of TRAIL expression on activated CD4 T cells in acute coronary syndrome. Atherosclerosis 2010; 213: 33–39. |t Atherosclerosis |v 213 |y 2010 |
| 999 | C | 5 | |a 10.1016/j.molmed.2007.11.004 |9 -- missing cx lookup -- |1 CY Wang |p 37 - |2 Crossref |u Wang CY, Liu PY, Liao JK . Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008; 14: 37–44. |t Trends Mol Med |v 14 |y 2008 |
| 999 | C | 5 | |a 10.1016/j.jss.2004.08.001 |9 -- missing cx lookup -- |1 RG Casey |p 176 - |2 Crossref |u Casey RG, Joyce M, Roche-Nagle G, Chen G, Bouchier-Hayes D . Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease. J Surg Res 2005; 123: 176–181. |t J Surg Res |v 123 |y 2005 |
| 999 | C | 5 | |a 10.1371/journal.pone.0028717 |9 -- missing cx lookup -- |1 M Úriz |p e28717 - |2 Crossref |u Úriz M, Sáez E, Prieto J, Medina JF, Banales JM . Ursodeoxycholic acid is conjugated with taurine to promote secretin-stimulated biliary hydrocholeresis in the normal rat. PLoS ONE 2011; 6: e28717. |t PLoS ONE |v 6 |y 2011 |
| 999 | C | 5 | |a 10.1016/j.bbmt.2013.10.014 |9 -- missing cx lookup -- |1 T Ruutu |p 135 - |2 Crossref |u Ruutu T, Juvonen E, Remberger M, Remes K, Volin L, Mattsson J et al. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biol Blood Marrow Transplant 2014; 20: 135–138. |t Biol Blood Marrow Transplant |v 20 |y 2014 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|